Maintenance therapy with oral ganciclovir after treatment of cytomegalovirus infection

Clinical Transplantation

Volumn 12, Issue 3, 1998, Pages 270-273

  Nankivell, Brian J ^a   Malouf, Monique A ^b   Russ, Graeme R ^c   Barclay, Peter ^a   Glanville, Allan R ^b   Allen, Richard D M ^a   O'Connell, Philip J ^a   Chapman, Jeremy R ^a  

^a WESTMEAD HOSPITAL   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

Cytomegalovirus infection; Oral ganciclovir; Transplantation

Indexed keywords

GANCICLOVIR;

ADULT; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIARRHEA; FEMALE; FOLLOW UP; HEART LUNG TRANSPLANTATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TRANSPLANTATION; LUNG TRANSPLANTATION; MAINTENANCE THERAPY; MALE; MORBIDITY; NAUSEA; ORAL DRUG ADMINISTRATION; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROPHYLAXIS;

ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HUMANS; MALE; ORGAN TRANSPLANTATION; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 0031837732     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. RUBBIN RH. The indirect effects of CMV infection on the outcome of organ transplantation. J Am Med Assoc 1989: 261: 3607.
2. SPECTOR SA, MCKINLEY GF, LALEZARI JP, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. New Engl J Med 1996: 334: 1491.
3. KLINGEL R, POST K, GOHLKE F, EHRENTHAL W, WAN-DEL E. Oral ganciclovir is safe and effective for prophylaxis and pre-emptive therapy of cytomegalovirus disease after kidney transplantation. Nephrology 1997: 3 (Suppl 1): 196 Abstract.
4. BRENNEN DC, SINGER GG, GASLOCK KA, SCHNITZLER MA, STORCH GA, Prophylactic oral ganciclovir prevents cytomegalovirus disease in renal transplant recipients. Nephrology 1997: 3 (Suppl 1): 197 Abstract.
5. GANE E, SALIBA F, VALDECASAS G, et al. Efficacy and safety of oral ganciclovir in the prevention of CMV disease in liver transplant recipients: results of a multicenter, multinational clinical trial (Abstract) 1996; American Society Transplant Surgeons, Annual Meeting, Chicago. 1996.
6. LAVELLE J, FOLLANSBEE S, TRAPNELL CB, et al. Effect of food on the relative bioavailability of oral ganciclovir. J Clin Pharmacol 1996: 36: 238.
7. PESCOVITZ MD, PRUETT TL, BROOK B, et al. Pharmacokinetics of oral ganciclovir in liver transplant recipients (abstract) 1996; American Society Transplant Physicans, Annual Meeting, Dallas, 1996.
8. MERIGAN TC, RENLUND DG, KEAY S, et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. New Engl J Med 1992. 326: 1182.
9. PAYA CV. Defining an optimal regimen for cytomegalovirus prophylaxis in organ transplant recipients. Transplant Proc 1996: 28 (Suppl 2): 9.
10. MARTIN M, SNYDMAN DR. How effective is oral ganciclovir? Transplant Proc 1996: 28 (Suppl 2): 14.